An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Trial Status: active
Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic
study with a dose expansion at the RP2D to evaluate safety and potential antitumor
activity of Q901 as a monotherapy and in combination with pembrolizumab
Inclusion Criteria
Participants with histologically or cytologically confirmed advanced or metastatic ovarian, CRPC, HR+ HER2- breast, endometrial, colorectal, small-cell lung, or pancreatic cancer, who have progressed following standard-of-care therapy or for whom there is no standard therapy that confers clinical benefit
Measurable disease per RECIST v 1.1
ECOG performance status 0,1 or 2
Life expectancy of at least 3 months
Age ≥ 18 years
Signed, written IRB-approved informed consent form
Exclusion Criteria
New York Heart Association Class III or IV cardiac disease, or myocardial infarction, severe unstable angina, coronary/peripheral artery bypass graft, congestive heart failure within the past 6 months
Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of >470 msec (females) and >450 msec (males)
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
Active, poorly controlled autoimmune or inflammatory diseases
Additional locations may be listed on ClinicalTrials.gov for NCT05394103.
